Display options
Cite
Jones GD, Caso R, Tan KS, et al. . Clin Cancer Res. 2021;27(9):2604-2612doi: 10.1158/1078-0432.CCR-20-4772.
Jones, G. D., Caso, R., Tan, K. S., Mastrogiacomo, B., Sanchez-Vega, F., Liu, Y., Connolly, J. G., Murciano-Goroff, Y. R., Bott, M. J., Adusumilli, P. S., Molena, D., Rocco, G., Rusch, V. W., Sihag, S., Misale, S., Yaeger, R., Drilon, A., Arbour, K. C., Riely, G. J., Rosen, N., Lito, P., Zhang, H., Lyden, D. C., Rudin, C. M., Jones, D. R., Li, B. T., & Isbell, J. M. (2021). . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2604-2612. https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones, Gregory D, et al. "." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2604-2612. doi: https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM. . Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16. PMID: 33593884; PMCID: PMC8102372.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16.

[No title available]

Clinical cancer research : an official journal of the American Association for Cancer Research

Gregory D Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G Connolly, Yonina R Murciano-Goroff, Matthew J Bott, Prasad S Adusumilli, Daniela Molena, Gaetano Rocco, Valerie W Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drilon, Kathryn C Arbour, Gregory J Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C Lyden, Charles M Rudin, David R Jones, Bob T Li, James M Isbell

Affiliations

  1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  3. Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
  4. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  6. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  7. Weill Cornell Medicine, New York, New York.
  8. Department of Pediatrics, Weill Cornell School of Medicine, New York, New York.
  9. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. [email protected] [email protected] [email protected].
  10. Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. [email protected] [email protected] [email protected].

PMID: 33593884 PMCID: PMC8102372 DOI: 10.1158/1078-0432.CCR-20-4772

[No abstract available.]

©2021 American Association for Cancer Research.

References

  1. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–51. - PubMed
  2. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457–67. - PubMed
  3. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50. - PubMed
  4. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2013;119:356–62. - PubMed
  5. Janne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crino L, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA. 2017;317:1844–53. - PubMed
  6. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7:122–36. - PubMed
  7. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 2010;17:S18–30. - PubMed
  8. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14:38–47. - PubMed
  9. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–23. - PubMed
  10. Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316–29. - PubMed
  11. Janes MR, Zhang JC, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172:578–89. - PubMed
  12. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604–8. - PubMed
  13. Xue JY, Zhao YL, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421–5. - PubMed
  14. Janne P PK, Ou I, Rybkin I, Johnson M. A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors. - PubMed
  15. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17. - PubMed
  16. Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, et al. Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2019;14:1095–101. - PubMed
  17. Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, et al. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2014;9:1513–22. - PubMed
  18. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251–64. - PubMed
  19. Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, et al. The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol. 2020;15:1844–56. - PubMed
  20. The Cancer Genome Atlas: lung adenocarcinoma. - PubMed
  21. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606–12. - PubMed
  22. Chang JC, Alex D, Bott M, Tan KS, Seshan V, Golden A, et al. Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res. 2019;25:7113–25. - PubMed
  23. Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131. - PubMed
  24. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011. - PubMed
  25. Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928–37. - PubMed
  26. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–21. - PubMed
  27. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AWT, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. - PubMed
  28. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13. - PubMed
  29. Serrano P, Hammond JA, Geralt M, Wuthrich K. Splicing site recognition by synergy of three domains in splicing factor RBM10. Biochemistry. 2018;57:1563–7. - PubMed
  30. Jones GD, Brandt WS, Shen R, Sanchez-Vega F, Tan KS, Martin A, et al. A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma: a prospective observational cohort study. JAMA Surg. 2021;156:e205601. - PubMed
  31. Papillon-Cavanagh S, Doshi P, Dobrin R, Szustakowski J, Walsh AM. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 2020;5:e000706. - PubMed
  32. Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2018;24:334–40. - PubMed
  33. Roman M, Baraibar I, Lopez I, Nadal E, Rolfo C, Vicent S, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17:33. - PubMed
  34. Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, et al. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer. 2019;133:144–50. - PubMed
  35. Testa U, Castelli G, Pelosi E. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers. 2018;10:248. - PubMed
  36. Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015;6:8258. - PubMed
  37. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21. - PubMed
  38. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015;5:704–12. - PubMed
  39. Salter JD, Bennett RP, Smith HC. The APOBEC protein family: united by structure, divergent in function. Trends Biochem Sci. 2016;41:578–94. - PubMed
  40. Chen H, Chong W, Teng C, Yao Y, Wang X, Li X.. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer. Cancer Sci. 2019;110:2348–56. - PubMed

Publication Types

Grant support